OXFORD BIODYNAMICS PLC Logo

OXFORD BIODYNAMICS PLC

OBD | IL

Overview

Corporate Details

ISIN(s):
GB00BD5H8572 (+2 more)
LEI:
2138005Y1TK258O5U928
Country:
United Kingdom
Address:
3140 ROWAN PLACE, JOHN SMITH DRIVE, OX4 2WB OXFORD
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. The company's core technology is the proprietary EpiSwitch® platform, which analyzes 3D genome regulation to discover and develop novel epigenetic biomarkers. Its primary products include the EpiSwitch® PSE, a blood test that detects the likelihood of prostate cancer with high accuracy to reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. Oxford BioDynamics focuses on translating genomic data into clinically actionable insights to improve diagnosis and treatment guidance.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for OXFORD BIODYNAMICS PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-13 08:00
Regulatory News Service
Collaboration with Google Cloud
English 12.0 KB
2025-07-18 16:11
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2025-07-17 08:01
Report Publication Announcement
GenomeWeb to host joint Agilent/OBD presentation
English 18.3 KB
2025-07-17 08:00
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-07-15 18:20
Major Shareholding Notification
Holding(s) in Company
English 23.2 KB
2025-07-15 08:00
Regulatory News Service
Pfizer study on EpiSwitch biomarkers
English 19.7 KB
2025-07-01 16:00
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-06-30 08:00
Earnings Release
Interim Results
English 706.2 KB
2025-06-27 14:30
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-03-28 11:35
Post-Annual General Meeting Information
Result of AGM
English 12.3 KB
2025-03-17 08:00
Board/Management Information
Board Changes
English 18.2 KB
2025-03-14 18:25
Major Shareholding Notification
Holding(s) in Company
English 23.2 KB
2025-03-13 08:00
Regulatory News Service
Expansion of OBD/Bupa UK insurance partnership
English 26.1 KB
2025-03-05 17:00
Report Publication Announcement
Publication of 2024 Annual Report
English 13.7 KB
2025-03-03 08:00
Remuneration Information
PDMR Dealing / Grant of Share Options
English 67.5 KB

Automate Your Workflow. Get a real-time feed of all OXFORD BIODYNAMICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for OXFORD BIODYNAMICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA